---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018600"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:43:34.780979+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference

## Summary
- CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.
- Oral presentation by co-CEO Sam Lee on Sept 11, 2025 at the 9th International Calicivirus Conference in Banff.
- Phase 1 study completed evaluating safety, tolerability, pharmacokinetics, and food effect in healthy adults.
- No approved vaccine or antiviral exists for norovirus; CDI-988 targets a conserved region of 3CL protease.

## SEC filing metadata
- accession: 0001641172-25-018600
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225018600/0001641172-25-018600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225018600/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018600
- JSON: https://secwatch.observer/filing/0001641172-25-018600.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.